

Resource Summary Report

Generated by [ASWG](#) on Aug 4, 2026

Cancer Dependency Map Portal

RRID:SCR_017655

Type: Tool

Proper Citation

Cancer Dependency Map Portal (RRID:SCR_017655)

Resource Information

URL: <https://depmap.org/portal/>

Proper Citation: Cancer Dependency Map Portal (RRID:SCR_017655)

Description: Portal for identifying genetic and pharmacologic dependencies and biomarkers that predicts them by providing access to datasets, visualizations, and analysis tools that are being used by Cancer Dependency Map Project at Broad Institute. Project to systematically identify genes and small molecule dependencies and to determine markers that predict sensitivity. All data generated by DepMap Project are available to public under CC BY 4.0 license on quarterly basis and pre-publication.

Abbreviations: DepMap Portal

Synonyms: Dependency Map Portal, Dependency Map portal, Cancer DepMap, Cancer Dependency Map Project

Resource Type: portal, database, catalog, data or information resource, project portal, data set

Keywords: Cancer, vulnerability, dataset, visualization, analysis, tool, catalog, biomarker, genetic, drug, sensitivity, tumor, model, FASEB list

Availability: Free, Available for download, Freely available

Resource Name: Cancer Dependency Map Portal

Resource ID: SCR_017655

Record Creation Time: 20220129T080336+0000

Record Last Update: 20260804T043642+0000

Ratings and Alerts

No rating or validation information has been found for Cancer Dependency Map Portal.

No alerts have been found for Cancer Dependency Map Portal.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1000 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Gou X, et al. (2026) Identification of a Two-Gene Biomarker Correlated with Sensitivity to Combined PARP7 Inhibition and AHR Activation in Cancer Cells. *Cancer research communications*, 6(1), 5.

Mogi M, et al. (2026) Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture. *British journal of cancer*, 134(1), 141.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Wnuk M, et al. (2025) Design of a Magnetic Nanoplatfrom Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells. *ACS biomaterials science & engineering*, 11(1), 280.

Pollin G, et al. (2025) Emergent properties of the lysine methylome reveal regulatory roles via protein interactions and histone mimicry. *Epigenomics*, 17(1), 5.

Zhao D, et al. (2025) Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening. *Neoplasia (New York, N.Y.)*, 60, 101100.

Christopher JA, et al. (2025) Global Proteomics Indicates Subcellular-Specific Anti-Ferroptotic Responses to Ionizing Radiation. *Molecular & cellular proteomics : MCP*, 24(1), 100888.

Johnson M, et al. (2025) Loss of SETD2 in wild-type VHL clear cell renal cell carcinoma sensitizes cells to STF-62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis. *Molecular oncology*, 19(4), 1244.

Dixon S, et al. (2025) A clinical drug candidate that triggers non-apoptotic cancer cell death. *Research square*.

Zhong S, et al. (2025) Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy. *Clinical and*

translational medicine, 15(3), e70177.

Xie X, et al. (2025) Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutations. *Nature*, 639(8053), 241.

van Kampen F, et al. (2025) Deletion of 17p in cancers: Guilt by (p53) association. *Oncogene*, 44(10), 637.

Tang L, et al. (2025) CXCL14 in prostate cancer: complex interactions in the tumor microenvironment and future prospects. *Journal of translational medicine*, 23(1), 9.

Belmontes B, et al. (2025) AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. *Cancer discovery*, 15(1), 139.

Li Y, et al. (2025) Identification and multi-omics analysis of essential coding and long non-coding genes in colorectal cancer. *Biochemistry and biophysics reports*, 41, 101938.

Masi M, et al. (2025) Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. *Cell death discovery*, 11(1), 106.

Esp??n R, et al. (2025) Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment. *NAR cancer*, 7(1), zcaf007.

Kougnassoukou Tchara PE, et al. (2025) Coupling Proximity Biotinylation with Genomic Targeting to Characterize Locus-Specific Changes in Chromatin Environments. *Journal of proteome research*, 24(4), 1845.

Yang R, et al. (2025) Increasing RB1 Expression by Targeting EZH2 in Triple-Negative Breast Cancer. *Journal of cellular and molecular medicine*, 29(5), e70384.